trial

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

NCTId NCT00209027
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 20 (actual)
Sponsored by Emory University
Primary completion 2010-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
20 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2005-04
Primary completion
2010-12
Eligibility
MALE · 20 Years · 50 Years

Interventions & indications

Drugs
fMRIAripiprazole

Sponsors

Emory UniversityLead Sponsor
Bristol-MyersCollaborator

Investigators

1
Erica J. Duncan, MDPrincipal Investigator

Sites

1 total
Decatur, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
NA
Primary Completion Date
2010-12
Status
TERMINATED
relationships
The graph out of here
drug
fMRI
drug
Aripiprazole
drug
lead_sponsor
Emory University
company
collaborator
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Erica J. Duncan, MD
person